ClinicalTrials.gg
Not yet recruitingNCT07843966Updated Sep 28, 2026

Persona Revision Knee System EMEA PMCF Study

An observational study in Severe Knee Pain, Severe Knee Disability and Revision Arthroplasty, sponsored by Zimmer, GmbH. Not yet recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Zimmer, GmbH · Observational

How we know

Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
238
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 268 studies in Pain with a site in Denmark — 36 open to participants now, 42 under way, none of them phase 3. Pain · Denmark.

Planned enrollment
15th of 53
238 · median 100
Started
2026
with 11 others
Observational
53 of 268
10 open now
Primary completion
2030-09
later than 39 of 41 live
Registered
266th of 268
by date

Among the 268 studies in Pain with a site in Denmark, this one is the 15th largest by planned enrollment of the 53 observational ones that give a count, is one of 12 that started in 2026, is one of 53 observational ones, reaches primary completion later than 39 of the 41 other live ones, and was the 266th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

36 of the 268 studies in Pain with a site in Denmark are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 268 studies in Pain with a site in Denmark, or all of them as a file.
02

Study summary

The purpose of this post-market clinical follow-up study is to confirm the long-term safety, performance and clinical benefits of the Persona Revision Knee System Implants and Instrumentation in revision Total Knee Arthroplasty.

Read the detailed description

Study Design:

This is a multicenter, Prospective, Non-controlled, Non-randomized, Consecutive series of patients, Dual cohort study.

Objectives:

  • Confirm the long-term safety, performance and clinical benefits of the Persona Revision Knee System Implants and its Instrumentation when used in revision TKA.
  • Confirm that, under normal use, the performance and clinical benefits of this device and its instrumentation conform to those intended by the manufacturer by recording Patient-Reported clinical Outcome Measures (PROMs) and radiographic outcomes (if standard of care).

Condition Being Treated/Target population:

The target population for this study consists of patients presenting with a clinically diagnosed necessity for revision total knee arthroplasty with severe knee pain or reduction in functionality resulting in the need for salvage of previously failed surgical attempts, or for a knee in which satisfactory stability in flexion cannot be obtained at the time of surgery

Per indication approved in the European Union and European Economic Area, only revision cases can be included in this study. Full or partial/hybrid revision cases that fall within the revision knee indication are allowed to be included in the study (not first joint replacement).

EC Approval:

The study will require each site to obtain Ethics Committee approval prior to study enrollment. All potential study subjects will be required to participate in the Informed Consent Process.

Length of Study:

12 years including at least 2 years of enrollment and 10 years of follow up.

Subjects must meet all the inclusion criteria and none of the exclusion criteria and receive the study device to participate in this study.

Study subjects will undergo preoperative clinical evaluations prior to their revision knee arthroplasty. The post-operative clinical and radiographic (if standard of care) evaluations will be conducted at 3 months, 1-year, 2-years, 3 -years, 5-years, 7-years and 10-years after implantation.

Data collection will de done in paper and electronic Case Report Forms (CRFs). CRFs will be completed either in-office or hospital at pre-operative, Surgery, Discharge, and the 3 months, 1-year, 2-year, and 5-year intervals. CRFs will be completed either in-office, by phone or by mail at the 3-year, 7-year, and 10-year intervals.

The PMCF is compliant with the following:

  • ISO 14155: 2020 - Clinical investigation of medical devices for human subjects - Good clinical practice
  • The Declaration of Helsinki (DoH) - Ethical principles for medical research involving human subjects
  • European Regulation (EU) 2017/745
  • MDCG 2020-10/1 Safety reporting in clinical investigations for medical devices under the Regulation (EU) 2017/745

Funding: Funding for this clinical study is made available by Zimmer Biomet to support clinical data collection, Ethic Committees review fees and other expenses associated with the conduct and execution of this study protocol

03

Conditions studied

  • Severe Knee Pain
  • Severe Knee Disability
  • Revision Arthroplasty

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing revision total knee arthroplasty with the Persona Revision Knee System who meet the study eligibility criteria at participating study sites.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient qualifies for a revision knee arthroplasty with the Persona Revision Knee System. Full or partial/hybrid revision cases that fall within the revision knee indication are allowed to be included in the study (not first joint replacement).
  • Patient experiences severe knee pain and disability due to:

The salvage of previously failed knee surgical attempts or for a knee in which satisfactory stability in flexion cannot be obtained at the time of surgery.

  • One-stage revision performed for infection OR
  • Second stage (reimplantation) of a planned two-stage revision.
  • Patient is ≥ 18 years.
  • Patient is skeletally mature.
  • Patient is willing and able to complete scheduled follow-up evaluations as described in the Protocol and Form.
  • Patient has participated in the Informed Consent process and is willing and able to sign the Informed Consent Form.

Exclusion criteria

Exclusion Criteria:

  • Patient received the study device for any condition not listed in the indications or in combination with a non-compatible device.
  • First Knee Replacement patients.
  • Patient with only inlay/bearing exchange/revision.
  • Patient requires simultaneous bilateral knee surgery for treatment of diagnosed condition.
  • Patient has any of the following :

    • Any active or suspected latent infection in or about the knee joint or distant foci of infection which may cause hematogenous spread to the implant site: In any case, the infection needs to be treated prior to the revision surgery.
    • Insufficient bone stock on femoral or tibial surfaces which cannot provide adequate support and/or fixation to the prosthesis.
    • Skeletal immaturity.
    • Neuropathic arthropathy.
    • Osteoporosis or any loss of musculature or neuromuscular disease that compromises the affected limb.
    • A stable, painless arthrodesis in a satisfactory functional position
    • Severe instability secondary to the absence of collateral ligament integrity.
    • Diagnosis of rheumatoid arthritis in conjunction with any of the following at the preoperative appointment: An ulcer of the skin, history of recurrent breakdown of the skin, use of .
  • Patients in whom the Persona Revision Knee System is used as a temporary, interim, spacer-type, or destination-spacer construct are not eligible, including use in a 1.5-stage revision strategy or as the first-stage construct in a planned 2-stage revision. Enrollment is restricted to subjects in whom the Persona Revision Knee System is implanted as the surgeon-intended definitive revision knee arthroplasty following infection eradication.
  • Patient underwent contralateral total knee arthroplasty within 3 months of the planned index procedure or has a contralateral total knee arthroplasty planned within 3 months of the index procedure.
  • Patient is known to be pregnant or planning to become pregnant during the time they will be participating in the study.
  • Patient is a member of a vulnerable population group, such as

    • A prisoner.
    • A known alcohol or drug abuser.
    • Mentally incompetent or unable to understand what participation in this study entails.
  • Patient with suspected or confirmed metal sensitivity or allergy to the metals of the device.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
238 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1: Persona Revision Knee + CCK articular surface

    From the total sample size (238 cases), 119 cases will be implanted with the Persona Revision Knee and the CCK articular surface.

  • Cohort 2: Persona Revision Knee + CPS or PS articular surface

    From the total sample size (238 cases), 119 cases will be implanted with the Persona Revision Knee and CPS or PS articular surface.

06

What researchers measure

Primary outcomes

  1. Change in Oxford Knee Score (OKS) from Baseline to 2 Years

    Average change in Oxford Knee Score (OKS) from baseline to 2 years follow-up. The average change will be evaluated against the Minimal Clinically Important Difference (MCID) of 4.0 points.

    Time frame: From baseline (pre-operative assessment) to 2 years after surgery

Secondary outcomes

  1. All-Cause Implant Survival

    All-cause survival of the implant system based on removal of any core system component (femoral component, tibial plate, or articular surface) for any reason

    Time frame: From surgery up to 10 years post-surgery

  2. Adverse events / Safety

    Safety of the Persona Revision Knee System assessed by the frequency and incidence of adverse events, including the relationship of events to the implant, instrumentation, and/or surgical procedure.

    Time frame: From surgery up to 10 years of follow-up

  3. Oxford Knee Score - follow-up beyond the primary endpoint

    Oxford Knee Score to assess knee pain and functional performance during follow-up. The Oxford Knee Score ranges from 0 to 48, with higher scores indicating better outcomes.

    Time frame: Baseline, 3 months, 1 year, 2 years, 3 years (optional), 5 years, 7 years (optional), and 10 years post-surgery

  4. EQ-5D-5L Health Related Quality of Life

    EQ-5D-5L to assess subject health-related quality of life during follow-up.Health-related quality of life will be assessed using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L). The descriptive system includes five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a 5-level scale, from level 1 (no problems) to level 5 (extreme problems or inability), with higher levels indicating worse health status. The EQ visual analogue scale (EQ VAS) ranges from 0 to 100, with higher scores indicating better self-rated health.

    Time frame: Baseline, 3 months, 1 year, 2 years, 3 years (optional), 5 years, 7 years (optional), and 10 years post-surgery

  5. Patient Satisfaction with the Study Knee and Treatment

    Patient Satisfaction Questionnaire to assess patient satisfaction with the study knee and treatment. Patient satisfaction with the study knee and treatment will be assessed using the Patient Satisfaction Questionnaire. The questionnaire includes three questions: usual knee pain during the past 4 weeks, satisfaction with the knee replacement, and willingness to undergo the surgery again. Responses are categorical and will be summarized descriptively; no total questionnaire score will be calculated. Knee pain is rated as None, Very mild, Mild, Moderate, or Severe, with higher severity indicating worse outcome. Satisfaction is rated as Very satisfied, Satisfied, Neutral, Dissatisfied, or Very dissatisfied, with higher satisfaction indicating better outcome. Willingness to undergo surgery again is recorded as Yes or No.

    Time frame: 3 months, 1 year, 2 years, 3 years (optional), 5 years, 7 years (optional), and 10 years post-surgery

  6. Percentage (%) of Participants with significant radiographic findings

    Presence or absence of significant radiographic findings will be assessed by standard-of-care radiographs. If a significant finding is identified, the type of finding is documented, including osteolysis, radiolucency, radiodensity, bone loss, subsidence, heterotopic ossification, fracture, implant loosening, articular surface wear, patellar dislocation, subluxation, tilt, or other significant findings. The amount of the finding may be recorded in millimeters (mm) or degrees, when applicable.

    Time frame: From baseline up to 10 years after surgery

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided — A decision regarding the sharing of individual participant data (IPD) has not yet been made and will be determined at a later stage of the study.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2030, 48 months later.

Of 520 observational studies under Pain, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 41. This study's planned 48 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2026
First posted
Sep 28, 2026
StartEst.
Sep 2026
Primary completionEst.
Sep 2030
CompletionEst.
Dec 2038
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07843966
Lead sponsor
Zimmer, GmbH
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2030 (estimated)
Completion
Dec 2038 (estimated)
Last update
Sep 28, 2026

Study contacts

Silvina Grasso, PhD
Contact
silvina.grasso@zimmerbiomet.com
0034674348191
Sabine Illi
Contact
sabine.Illi@zimmerbiomet.com
0041792014430
Anders Troelsen, MD, PhD
principal investigator · Hvidovre University Hospital, Copenhagen, Denmark
Fernando Martinez Delgado, MD, PhD
principal investigator · Hospital Universitario Miguel Servet, Zaragoza, Spain

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion